登录 | 注册    关注公众号  
微信公众号
搜索
 > 【TFPI】

TFPI信息

英文名称:Tissue factor pathway inhibitor
中文名称:组织因子通道抑制剂
靶点别称:TFPI,Tissue Factor Pathway Inhibitor,Extrinsic Pathway Inhibitor,TFPI1,LACI,EPI,Anti-Convertin,TFI,Lipoprotein-associated coagulation inhibitor,Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor)
上市药物数量:0
临床药物数量:3
最高研发阶段:临床三期

TFPI产品列表

 
评论(1)
TFI-H5226|Human TFPI Protein, His Tag (active enzyme)
  1. 151XXXXXXX5
  2. 5人赞
  3. 我们是先购买的小规格的Human TFPI蛋白,进行实验之后发现效果不错,于是购买了1mg规格的蛋白,用于后续实验,之后应该会继续选择该蛋白用于后续实验,相较于其他厂家,价格有优势,主要是货期也比较短,非常不错。
  4. >
  5. 2021-11-08
 

TFPI 分子别名

TFPI,LACI,TFPI1,EPI,TFI

TFPI 分子背景

Tissue factor pathway inhibitor (TFPI) is also known as Extrinsic pathway inhibitor (EPI), Lipoprotein - associated coagulation inhibitor (LACI), is a plasma proteinase inhibitor synthesized by vascular endothelial cells and part of it is associated with glycosaminoglycans of these cells. TFPI is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa) and Thrombin (Factor IIa). TFPI is a secreted protein with a N­terminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a C­terminal basic region. The first K domain inhibits coagulation factor VIIa complexed to tissue factor (TF); The second K domain inhibits factor Xa; The third K domain binds to heparin; The C­terminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces.

TFPI 前沿进展

TFPI临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Befovacimab BAY-109; BAY-1093884 Morphosys Ag, 拜耳 详情
ARC-19499 BAX-499; ARC-19499 Archemix 详情
KN-057 KN-057 临床二期 苏州康宁杰瑞生物科技有限公司 血友病A, 血友病B 详情
Concizumab NN-7415; mAb-2021; Anti-TFPI; mAbTFPI2021; NNC-172-2021; NNC-0172-2021; NNC-0172-0000-2021 临床三期 诺和诺德制药 血友病A, 血友病B, 出血 详情
Marstacimab PF-6741086; PF-06741086 临床三期 辉瑞制药有限公司 血友病A, 血友病B, 出血 详情

消息提示

请输入您的联系方式,再点击提交!

确定